DK2753334T3 - Fap-aktiverede proteasomhæmmere til behandling af solide tumorer - Google Patents
Fap-aktiverede proteasomhæmmere til behandling af solide tumorer Download PDFInfo
- Publication number
- DK2753334T3 DK2753334T3 DK12827686.2T DK12827686T DK2753334T3 DK 2753334 T3 DK2753334 T3 DK 2753334T3 DK 12827686 T DK12827686 T DK 12827686T DK 2753334 T3 DK2753334 T3 DK 2753334T3
- Authority
- DK
- Denmark
- Prior art keywords
- fap
- treatment
- solid tumors
- proteasome inhibitors
- activated proteasome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161528824P | 2011-08-30 | 2011-08-30 | |
PCT/US2012/053140 WO2013033396A2 (en) | 2011-08-30 | 2012-08-30 | Fap-activated proteasome inhibitors for treating solid tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2753334T3 true DK2753334T3 (da) | 2022-11-07 |
Family
ID=47757170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12827686.2T DK2753334T3 (da) | 2011-08-30 | 2012-08-30 | Fap-aktiverede proteasomhæmmere til behandling af solide tumorer |
Country Status (14)
Country | Link |
---|---|
US (5) | US9597410B2 (da) |
EP (2) | EP4144354A1 (da) |
JP (2) | JP6207509B2 (da) |
CN (2) | CN103945856A (da) |
AU (2) | AU2012301810B2 (da) |
CA (1) | CA2846852C (da) |
DK (1) | DK2753334T3 (da) |
ES (1) | ES2929179T3 (da) |
HR (1) | HRP20221320T1 (da) |
HU (1) | HUE060305T2 (da) |
PL (1) | PL2753334T3 (da) |
PT (1) | PT2753334T (da) |
SI (1) | SI2753334T1 (da) |
WO (1) | WO2013033396A2 (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2753334T3 (pl) * | 2011-08-30 | 2022-12-12 | Trustees Of Tufts College | Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych |
BR112015012885A2 (pt) * | 2012-12-03 | 2017-07-11 | Hoffmann La Roche | composições triazol e imidazol substituídas |
US20170035917A1 (en) * | 2013-06-10 | 2017-02-09 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
JP6468562B2 (ja) * | 2013-11-21 | 2019-02-13 | 国立大学法人北海道大学 | プロテアソーム阻害性化合物 |
US10245248B2 (en) | 2014-06-13 | 2019-04-02 | Bach Biosciences, Llc | FAP-activated therapeutic agents, and uses related thereto |
US9737556B2 (en) | 2014-06-13 | 2017-08-22 | Trustees Of Tufts College | FAP-activated therapeutic agents, and uses related thereto |
AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
PT3166933T (pt) | 2014-07-14 | 2018-12-06 | Centrax Int Inc | Compostos de epoxicetona para inibição de enzimas |
CN104231047B (zh) * | 2014-08-22 | 2017-06-16 | 亚飞(上海)生物医药科技有限公司 | 水溶性靶向激活的紫杉醇衍生物及其制备和用途 |
US10682371B2 (en) | 2014-08-22 | 2020-06-16 | Yafei Shanghai Biolog Medicine Science & Technology Co. Ltd. | Small molecule conjugates specifically activated in tumor microenvironment for targeting and use thereof |
US10675364B2 (en) * | 2015-06-23 | 2020-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Rhodol fluorophores for near-infrared imaging |
CN106588965A (zh) | 2015-10-15 | 2017-04-26 | 北京大学 | 脲拟肽硼酸化合物及其药物组合物、制备方法和用途 |
CN105938123B (zh) * | 2015-12-18 | 2018-09-14 | 重庆两江药物研发中心有限公司 | 一种卡非佐米中间体中杂质的检测方法 |
EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
CN109476637B (zh) | 2016-06-21 | 2022-02-01 | 奥瑞恩眼科有限责任公司 | 杂环脯氨酰胺衍生物 |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
AU2017292646A1 (en) | 2016-07-05 | 2019-02-07 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
SG10201912574WA (en) | 2016-09-28 | 2020-02-27 | Blade Therapeutics Inc | Calpain modulators and therapeutic uses thereof |
WO2018111989A1 (en) | 2016-12-14 | 2018-06-21 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
MA47215A (fr) | 2017-01-09 | 2019-11-13 | Bioxcel Therapeutics Inc | Procédés prédictifs et diagnostiques pour le cancer de la prostate |
EP3606939A4 (en) * | 2017-04-04 | 2021-01-20 | F. Hoffmann-La Roche AG | SUBSTRATES RECOGNIZED BY FIBROBLAST ACTIVATION PROTEIN (FAP) AND METHOD OF USING THEM |
KR102005030B1 (ko) * | 2017-10-31 | 2019-07-29 | 충북대학교 산학협력단 | 프로테아좀 억제제를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물 |
CN108191957B (zh) * | 2017-12-30 | 2021-05-04 | 浙江大学 | 三肽大环衍生物及其制备方法和应用 |
CN111867573A (zh) | 2018-01-29 | 2020-10-30 | 科诺斯治疗学公司 | 硼替佐米的瘤内递送 |
IL276594B2 (en) * | 2018-02-06 | 2023-11-01 | Univ Heidelberg | FAP inhibitors |
BR112021001963B1 (pt) | 2018-08-02 | 2024-02-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Compostos de borato de um derivado de azetidina, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para prevenção ou tratamento de mieloma múltiplo |
EP3833374A4 (en) * | 2018-08-06 | 2022-04-27 | University Of Kentucky Research Foundation | PROTEASOME INHIBITORS |
GB201820320D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
WO2021072212A1 (en) * | 2019-10-11 | 2021-04-15 | Mayo Foundation For Medical Education And Research | Proteasome inhibitors |
CN111235221B (zh) * | 2020-01-22 | 2022-08-05 | 北京大学第一医院 | 一种fap抑制剂的活性检测方法 |
CZ309380B6 (cs) | 2020-03-30 | 2022-10-26 | Ústav organické chemie a biochemie AV ČR v. v. i | Sloučeniny pro inhibici fibroblastového aktivačního proteinu |
CN115968411A (zh) * | 2020-06-17 | 2023-04-14 | 犹他大学研究基金会 | 基于生物标记的用于蛋白酶体抑制剂治疗的患者选择 |
JP2023554396A (ja) * | 2020-12-17 | 2023-12-27 | トラスティーズ オブ タフツ カレッジ | Fap活性化ラジオセラノスティクスおよび関連する使用 |
US20240101549A1 (en) | 2020-12-17 | 2024-03-28 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
ZA86746B (en) | 1985-02-04 | 1986-09-24 | Merrell Dow Pharma | Novel peptidase inhibitors |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
DE69535019T2 (de) | 1994-03-11 | 2007-01-04 | Wilson Greatbatch, Ltd. | Elektromagnetische pumpe mit geringem vermögen |
US5580979A (en) | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6180402B1 (en) | 1996-11-20 | 2001-01-30 | Qlt Inc. | Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor |
ES2285785T3 (es) | 1997-09-29 | 2007-11-16 | Point Therapeutics, Inc. | Estimulacion de celulas hematopoyeticas in vitro. |
CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
MY132924A (en) | 1998-05-04 | 2007-10-31 | Point Therapeutics Inc | Hematopoietic stimulation |
WO1999062914A1 (en) | 1998-06-05 | 1999-12-09 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
CA2362620A1 (en) | 1999-02-11 | 2000-08-17 | Joseph A. Stets | Power supply |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
EP1487471A4 (en) | 2001-11-26 | 2010-03-10 | Tufts College | METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS |
CA2468192A1 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
AU2003228793B2 (en) | 2002-04-30 | 2008-01-03 | Trustees Of Tufts College | Smart Pro-Drugs of Serine Protease Inhibitors |
AU2003248921A1 (en) | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
CA2525574C (en) | 2003-05-15 | 2015-06-30 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
BRPI0507972A (pt) | 2004-02-23 | 2007-07-24 | Tufts College | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada |
US20060063719A1 (en) | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
JP2008545661A (ja) | 2005-05-19 | 2008-12-18 | ジェネンテック・インコーポレーテッド | 線維芽細胞活性化タンパク質阻害剤化合物および |
KR20080030079A (ko) * | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
JP5270369B2 (ja) * | 2005-12-19 | 2013-08-21 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | ソフトプロテアーゼ抑制剤およびそのプロソフト型 |
US20080004286A1 (en) * | 2006-06-30 | 2008-01-03 | Schering Corporation | Method of Using Substituted Piperidines that Increase P53 Activity |
WO2008116053A2 (en) * | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Fap-activated chemotherapeutic compounds, and methods of use thereof |
AU2008228863A1 (en) * | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
WO2009006473A2 (en) * | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
MY161991A (en) * | 2007-08-06 | 2017-05-31 | Millennium Pharm Inc | Proteasome inhibitors |
AU2008290582B2 (en) * | 2007-08-17 | 2014-08-14 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
WO2009111470A2 (en) * | 2008-03-03 | 2009-09-11 | Kansas State University Research Foundation | Protease assay |
JP5801585B2 (ja) | 2011-03-30 | 2015-10-28 | 株式会社ケーヒン | 燃料噴射制御システム |
PL2753334T3 (pl) | 2011-08-30 | 2022-12-12 | Trustees Of Tufts College | Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych |
-
2012
- 2012-08-30 PL PL12827686.2T patent/PL2753334T3/pl unknown
- 2012-08-30 WO PCT/US2012/053140 patent/WO2013033396A2/en active Application Filing
- 2012-08-30 JP JP2014528600A patent/JP6207509B2/ja active Active
- 2012-08-30 US US14/241,666 patent/US9597410B2/en active Active
- 2012-08-30 CA CA2846852A patent/CA2846852C/en active Active
- 2012-08-30 HR HRP20221320TT patent/HRP20221320T1/hr unknown
- 2012-08-30 DK DK12827686.2T patent/DK2753334T3/da active
- 2012-08-30 CN CN201280052940.4A patent/CN103945856A/zh active Pending
- 2012-08-30 HU HUE12827686A patent/HUE060305T2/hu unknown
- 2012-08-30 ES ES12827686T patent/ES2929179T3/es active Active
- 2012-08-30 AU AU2012301810A patent/AU2012301810B2/en active Active
- 2012-08-30 EP EP22201696.6A patent/EP4144354A1/en active Pending
- 2012-08-30 CN CN201810059355.6A patent/CN108383893A/zh active Pending
- 2012-08-30 SI SI201232012T patent/SI2753334T1/sl unknown
- 2012-08-30 EP EP12827686.2A patent/EP2753334B1/en active Active
- 2012-08-30 PT PT128276862T patent/PT2753334T/pt unknown
-
2016
- 2016-05-27 US US15/167,109 patent/US9956297B2/en active Active
-
2017
- 2017-06-19 AU AU2017204121A patent/AU2017204121A1/en not_active Abandoned
- 2017-09-05 JP JP2017170106A patent/JP2018016629A/ja active Pending
-
2018
- 2018-04-13 US US15/952,648 patent/US10517955B2/en active Active
-
2019
- 2019-11-19 US US16/688,574 patent/US11065339B2/en active Active
-
2021
- 2021-06-15 US US17/348,043 patent/US20210379190A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE060305T2 (hu) | 2023-02-28 |
SI2753334T1 (sl) | 2023-01-31 |
US9956297B2 (en) | 2018-05-01 |
PT2753334T (pt) | 2022-11-03 |
CN103945856A (zh) | 2014-07-23 |
HRP20221320T1 (hr) | 2023-01-06 |
US11065339B2 (en) | 2021-07-20 |
CA2846852A1 (en) | 2013-03-07 |
US20210379190A1 (en) | 2021-12-09 |
US20190054181A1 (en) | 2019-02-21 |
JP2014527070A (ja) | 2014-10-09 |
US10517955B2 (en) | 2019-12-31 |
EP2753334B1 (en) | 2022-10-19 |
PL2753334T3 (pl) | 2022-12-12 |
EP4144354A1 (en) | 2023-03-08 |
EP2753334A2 (en) | 2014-07-16 |
ES2929179T3 (es) | 2022-11-25 |
AU2017204121A1 (en) | 2017-07-06 |
US9597410B2 (en) | 2017-03-21 |
AU2012301810A1 (en) | 2014-04-10 |
US20200323994A1 (en) | 2020-10-15 |
CN108383893A (zh) | 2018-08-10 |
US20160346401A1 (en) | 2016-12-01 |
JP6207509B2 (ja) | 2017-10-04 |
WO2013033396A3 (en) | 2014-05-08 |
AU2012301810B2 (en) | 2017-06-01 |
WO2013033396A2 (en) | 2013-03-07 |
JP2018016629A (ja) | 2018-02-01 |
EP2753334A4 (en) | 2015-07-01 |
CA2846852C (en) | 2021-01-12 |
US20140255300A1 (en) | 2014-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2753334T3 (da) | Fap-aktiverede proteasomhæmmere til behandling af solide tumorer | |
SMT201700109B (it) | Inibitori di istone demetilasi | |
DK3400944T3 (da) | Ibat-inhibitorer til behandling af leversygdomme | |
DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
DK3628670T3 (da) | Saltform til ezh2-hæmning | |
CO6930358A2 (es) | Compuestos inhibidores de metaloenzimas | |
DK2558105T3 (da) | Bardoxolonmethyl til behandling af fedme | |
DK3329775T3 (da) | Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser | |
DK3483143T3 (da) | Piperidinonderivater som mdm2-inhibitorer til behandlingen af kræft | |
DK2718404T3 (da) | Fremgangsmåde til fremstilling af flydende carbonhydrider | |
SMT201600328B (it) | Nuovi composti come inibitori di diacilglicerolo aciltransferasi | |
DK3412687T3 (da) | Fremgangsmåder til behandling af dlbcl | |
DK2785801T4 (da) | Fremgangsmåde til formindskelse af isdannelse på et underlag | |
DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
DK3581199T3 (da) | Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis | |
DK2715352T3 (da) | Fremgangsmåde til vurdering af risiko for pml | |
DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi | |
DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
DK2561890T3 (da) | Fremgangsmåde til fremstilling af medikamenter til bekæmpelse af tumorer | |
DK3536410T3 (da) | Fremgangsmåde til behandling af affaldsgenstande | |
DK2655360T3 (da) | Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler | |
DK2681377T3 (da) | Arrangement til fjernelse af istapper | |
CR20130603A (es) | Compuestos novedosos como inhibidores de diacilglicerol | |
DK2500036T3 (da) | MET-hæmmere til øgning af virkningen af radioterapi |